Is Fractyl poised to create a new MedTech market by helping former GLP-1 users keep weight off?

In this episode of the DeviceTalks Weekly Podcast, Host Tom Salemi is joined by Harith Rajagopalan, MD, PhD, co-founder and CEO of Fractyl Health. Dr. Rajagopalan explains why Fractyl shifted its focus from treating type 2 diabetes to helping former GLP-1 users maintain their weight loss with Revita, an outpatient endoscopic procedure designed to target the root causes of metabolic disease in the duodenum. He also shares new clinical data, the strategy behind Fractyl's pivotal trial, the company's commercialization plans, and why he believes metabolic endoscopy could become an entirely new category of care. This episode is brought to you by the  DeviceTalks Interventional Innovations series, July 28-30th. To register for this complimentary series, click here. *** Enjoy the show? Follow DeviceTalks Weekly on all major podcast players + Follow us on YouTube.com/@DeviceTalks to ensure you never miss an episode. Want access to the complete DeviceTalks Podcast Network (DTPN)? Follow us today at https://devicetalks.castos.com/subscribe Chapters (00:01:35) - Keynote Interview - Harith Rajagopalan, MD, PhD, Co-Founder and Chief Executive Officer, Fractyl Health(00:06:26) - Starting with Back of the Napkin Idea(00:18:45) - Why patients are enthusiastic(00:24:35) - The Parallels to Renal Denervation(00:29:40) - Commercial Plans, Pivotal Trials & What's Next